Back to Search
Start Over
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
- Source :
-
Circulation [Circulation] 2020 Jun 02; Vol. 141 (22), pp. 1829-1831. Date of Electronic Publication: 2020 Jun 01. - Publication Year :
- 2020
- Subjects :
- Anticholesteremic Agents therapeutic use
Ezetimibe therapeutic use
Gene Knockdown Techniques
Homozygote
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Hyperlipoproteinemia Type II drug therapy
Hyperlipoproteinemia Type II genetics
Hyperlipoproteinemia Type II metabolism
Pilot Projects
Proof of Concept Study
Proprotein Convertase 9 biosynthesis
Proprotein Convertase 9 genetics
RNA, Small Interfering adverse effects
RNA, Small Interfering genetics
RNA, Small Interfering pharmacology
Treatment Outcome
Cholesterol, LDL biosynthesis
Genetic Therapy
Hyperlipoproteinemia Type II therapy
Molecular Targeted Therapy
PCSK9 Inhibitors
RNA Interference
RNA, Small Interfering therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4539
- Volume :
- 141
- Issue :
- 22
- Database :
- MEDLINE
- Journal :
- Circulation
- Publication Type :
- Report
- Accession number :
- 32479195
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.119.044431